Catabasis Reports First Quarter 2017 Financial Results And Reviews Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2017, and reviewed recent business progress.

“We made important progress across our portfolio in the first quarter, including the presentation of encouraging results from our edasalonexent MoveDMD trial and the advancement of our rare disease pipeline,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “Our recently completed prespecified analysis of functional assessments in Part B of the MoveDMD trial strengthens our confidence in the potential of edasalonexent as a novel treatment for boys with Duchenne muscular dystrophy.”

Dr. Milne continued, “We see consistent numerical improvements across prespecified functional analyses of boys treated with edasalonexent. We expect to report interim results from Part C of the MoveDMD trial in the third quarter, and we look forward to gaining important information on the persistence of treatment signals with edasalonexent as well as determining functional endpoints for possible future clinical trials. The MoveDMD trial is progressing as planned, and we are focused on the next steps for the development of edasalonexent while continuing to advance our pipeline programs in cystic fibrosis and neurodegenerative diseases.”